Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature
- PMID: 31371806
- DOI: 10.1038/s41379-019-0325-6
Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature
Abstract
Myeloid neoplasms occasionally occur in patients with sickle cell disease, and the underlying connection between the two diseases is unclear. Herein, we retrospectively analyzed four cases of sickle cell disease patients who developed myeloid neoplasm. Age at time of diagnosis ranged from 27 to 59 years with a median of 35.5 years. Two patients were treated with hydroxyurea and the other two with supportive care alone, with one out of the four patients receiving additional treatment with hematopoietic stem cell transplant. Three patients presented with leukocytosis, and the remaining patient presented with pancytopenia. Two patients were diagnosed with myelodysplastic syndrome/myeloproliferative neoplasm, one with myelodysplastic syndrome, and the other with acute myeloid leukemia. All four cases demonstrated certain degrees of myelodysplasia and complex cytogenetic abnormalities with - 7/7q- and/or - 5/5q- or with 11q23 (KMT2A) rearrangement. This cytogenetic profile resembles that seen in therapy-related myeloid neoplasm, suggesting that myeloid neoplasm in the setting of sickle cell disease may represent a subcategory of the disease distinct from de novo myeloid neoplasm in general. Extensive literature review further demonstrates this similarity in cytogenetic profile, as well as in other associated pathologic features. Potential etiology includes therapy for sickle cell disease, disease-related immunomodulation, or disease-related chronic inflammation. We hypothesize that constant hematopoietic hyperplasia, stimulated by a hemolysis-induced cytokine storm, may increase the chance of somatic mutations/cytogenetic aberrations, resulting in transformation of myeloid precursors. This group of myeloid neoplasms seems to herald a dismal clinical outcome, with median survival <1 year, although the exact pathogenesis and biology of the disease remain to be investigated by large cohorts in future studies.
Similar articles
-
Sickle cell disease and acute leukemia: one case report and an extensive review.Ann Hematol. 2023 Jul;102(7):1657-1667. doi: 10.1007/s00277-023-05294-3. Epub 2023 Jun 3. Ann Hematol. 2023. PMID: 37269388 Free PMC article. Review.
-
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.Leuk Res. 2020 Aug;95:106402. doi: 10.1016/j.leukres.2020.106402. Epub 2020 Jun 18. Leuk Res. 2020. PMID: 32590108
-
Relapse and cytogenetic evolution in myeloid neoplasms.Panminerva Med. 2017 Dec;59(4):308-319. doi: 10.23736/S0031-0808.17.03380-8. Panminerva Med. 2017. PMID: 29144072 Review.
-
Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.Pathol Res Pract. 2019 Dec;215(12):152704. doi: 10.1016/j.prp.2019.152704. Epub 2019 Oct 22. Pathol Res Pract. 2019. PMID: 31699472
-
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.Am J Clin Pathol. 2012 Dec;138(6):855-66. doi: 10.1309/AJCPOP7APGDT9JIU. Am J Clin Pathol. 2012. PMID: 23161720
Cited by
-
Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.Mol Ther. 2021 Nov 3;29(11):3163-3178. doi: 10.1016/j.ymthe.2021.10.002. Epub 2021 Oct 8. Mol Ther. 2021. PMID: 34628053 Free PMC article. Review.
-
Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.Blood. 2020 Apr 2;135(14):1185-1188. doi: 10.1182/blood.2019004001. Blood. 2020. PMID: 32062672 Free PMC article. Clinical Trial.
-
Acute Promyelocytic Leukemia in a Patient With Sickle Cell Hemoglobin D Disease: A Case Report.Cureus. 2025 Jul 8;17(7):e87513. doi: 10.7759/cureus.87513. eCollection 2025 Jul. Cureus. 2025. PMID: 40777672 Free PMC article.
-
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.Nat Med. 2022 Jan;28(1):63-70. doi: 10.1038/s41591-021-01554-9. Epub 2022 Jan 3. Nat Med. 2022. PMID: 34980909 Free PMC article. Clinical Trial.
-
Gene therapy for sickle cell disease: where we are now?Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889358 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical